Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Google

- PMLiVE

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali

AstraZeneca AZ

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

The AI revolution – Ben Greenberg

Four Health - Emerging Technologies Artificial intelligence - Programmes with the ability to learn and reason like humans. Machine Learning - Algorithms with the ability to learn without being explicitly...

Four Health

Artificial Intelligence in healthcare

Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look.

IGNIFI

The AI revolution – Ben Greenberg

Four Health

Emerging Technologies

Four Health hosted an event on Emerging Technologies.

Four Health

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

- PMLiVE

Google boosts healthcare business with new hire

Tech giant shows ambition in US market

Eli Lilly HQ

Lilly gets EMA nod for Verzenio in breast cancer

And puts pressure on Pfizer’s market leading Ibrance and Novartis’ Kisqali

- PMLiVE

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Contender could offer potency without dose-limiting toxicities

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links